S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14

Axcella Health (AXLA) Stock Forecast, Price & News

+0.06 (+3.90%)
(As of 05/18/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
20,275 shs
Average Volume
35,174 shs
Market Capitalization
$84.13 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

Axcella Health logo

About Axcella Health

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.57 per share


Net Income
$-64.63 million
Pretax Margin




Free Float
Market Cap
$84.13 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.36 out of 5 stars

Medical Sector

225th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

33rd out of 210 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

Is Axcella Health a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axcella Health stock.
View analyst ratings for Axcella Health
or view top-rated stocks.

Are investors shorting Axcella Health?

Axcella Health saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 144,600 shares, a decline of 14.5% from the April 15th total of 169,200 shares. Based on an average trading volume of 97,900 shares, the short-interest ratio is currently 1.5 days. Approximately 0.7% of the company's stock are sold short.
View Axcella Health's Short Interest

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Axcella Health

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) released its quarterly earnings results on Wednesday, March, 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03. During the same quarter last year, the business posted ($0.40) EPS.
View Axcella Health's earnings history

What price target have analysts set for AXLA?

7 Wall Street analysts have issued 1-year target prices for Axcella Health's stock. Their forecasts range from $5.00 to $14.00. On average, they anticipate Axcella Health's stock price to reach $8.20 in the next year. This suggests a possible upside of 412.5% from the stock's current price.
View analysts' price targets for Axcella Health
or view top-rated stocks among Wall Street analysts.

Who are Axcella Health's key executives?
Axcella Health's management team includes the following people:
  • Mr. William R. Hinshaw Jr., Pres, CEO & Director (Age 53, Pay $812.05k) (LinkedIn Profile)
  • Mr. Laurent Chardonnet, Consultant (Age 57, Pay $576.06k)
  • Mr. Robert W. Crane, Sr. VP & CFO (Age 63)
  • Dr. Alison D. Schecter M.D., Pres of R&D, Strategy and Operations (Age 58)
  • Dr. Paul Fehlner J.D., Ph.D., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 58)
  • Ms. Virginia R. Dean, Sr. VP & Chief People Officer (Age 56)
  • Dr. Larry Bell, Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
  • Dr. Margaret James Koziel M.D., Sr. VP & Chief Medical Officer (Age 62)
  • Mr. Karim Azer Ph.D., VP of Systems Biology & Discovery
What is Bill Hinshaw's approval rating as Axcella Health's CEO?

3 employees have rated Axcella Health CEO Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among Axcella Health's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by many different retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (35.88%), Vanguard Group Inc. (1.44%), Edgewood Management LLC (0.19%), Pinnacle Private Wealth LLC (0.06%), Cutter & CO Brokerage Inc. (0.04%) and Simplex Trading LLC (0.00%). Company insiders that own Axcella Health stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Paul Fehlner, Robert Crane and William Hinshaw.
View institutional ownership trends for Axcella Health

Which major investors are selling Axcella Health stock?

AXLA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Cutter & CO Brokerage Inc..
View insider buying and selling activity for Axcella Health
or view top insider-selling stocks.

Which major investors are buying Axcella Health stock?

AXLA stock was bought by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., Edgewood Management LLC, Pinnacle Private Wealth LLC, and Simplex Trading LLC. Company insiders that have bought Axcella Health stock in the last two years include David R Epstein, Des Produits Nestle S Societe, Paul Fehlner, Robert Crane, and William Hinshaw.
View insider buying and selling activity for Axcella Health
or or view top insider-buying stocks.

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $1.60.

How much money does Axcella Health make?

Axcella Health has a market capitalization of $84.13 million. The company earns $-64.63 million in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does Axcella Health have?

Axcella Health employs 59 workers across the globe.

What is Axcella Health's official website?

The official website for Axcella Health is www.axcellahealth.com.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 320-2200, via email at [email protected], or via fax at 617-441-6243.

This page was last updated on 5/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.